课题基金 / 基金详情

SANDOSTATIN LAR IN PATIENTS W/ ACROMEGALY

SANDOSTATIN LAR IN PATIENTS W/ ACROMEGALY
善宁 LAR 用于肢端肥大症患者
批准号:
6264648
负责人:
DAVID L KLEINBERG
金额:
$2.1万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

DAVID L KLEINBERG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This Phase IIIb, open-label clinical trial attempts to document the ability of Sandostatin LAR, a long-acting ocreotide, to obtain and/or maintain normalized IGF-1 levels. The trial hopes to acheive other objectives including documentation of Sandostatin LAR 's ability to obtain and/or maintain therapeutic GH levels, and to relieve clinical signs and symptoms of acromegaly. Quality of life issues will also be assessed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SURGICAL DEBULKING PLUS OCTREOTIDE VERSUS OCTREOTIDE ALONE IN ACROMEGALY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
Prevalence of Growth Hormone Deficiency & Ranges of IGF-1 in Normal Elderly
海外基金